20/20 Biolabs (AIDX)

The company’s principal product platform is OneTest. OneTest for Cancer is positioned as a multi-cancer early detection blood test that evaluates biomarkers associated with cancer risk and is the company’s primary post-COVID revenue source. Rather than focusing on a single tumor type, the product is intended to support broader screening and risk assessment, an area of diagnostics that has attracted growing interest as healthcare systems look for tools that may complement established screening methods.

20/20 Biolabs also offers OneTest for Longevity, which uses inflammatory biomarkers to provide information related to health status and aging-associated risk factors. This product reflects the company’s broader emphasis on preventive health, where laboratory data may be used to guide follow-up care, lifestyle decisions, or additional clinical evaluation.

A distinctive aspect of 20/20 Biolabs is its combination of commercial diagnostics and data-driven software. By incorporating machine learning and accumulated real-world testing data, the company seeks to refine interpretation over time and improve the clinical utility of its reports. For investors, AIDX represents exposure to the early-detection diagnostics market, including the expanding but competitive field of blood-based cancer screening and preventive testing.